Business Context and Reporting Period
Company: Arvinas, Inc. (ARVN)
Filing Type: Form 8-K (Current Report)
Date: May 16, 2024
Subject: Regulation FD Disclosure and Other Events regarding updated clinical data for vepdegestrant in combination with palbociclib (IBRANCE®). The data, with a cutoff of December 18, 2023, was presented at the 2024 ESMO Breast Cancer Annual Congress and represents six months of additional follow-up from data presented in December 2023.
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on clinical trial updates and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data Updates
The filing details updated results from the Phase 1b ARV-471-mBC-101 study (NCT04072952) evaluating vepdegestrant (an investigational PROTAC ER degrader) plus palbociclib in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer. Key findings consistent with prior data include:
- Clinical Benefit Rate (CBR): 63% across all dose levels (n=46); 72% in patients with mutant ESR1; 53% in wild-type ESR1.
- Overall Response Rate (ORR): 42% in evaluable patients (n=31); 53% at the recommended Phase 3 dose (RP3D) of 200 mg.
- Median Progression-Free Survival (mPFS): 11.2 months across all dose levels; 13.9 months at the RP3D of 200 mg.
- ctDNA Analysis: Marked reduction (median change -98.9%) in tumor fraction after one treatment cycle across all dose groups.
- Safety: Consistent with prior reports. Grade 3/4 treatment-related adverse events included neutropenia (91%) and decreased white blood cell count (15%). No Grade 5 TRAEs or febrile neutropenia were reported.
Outlook, Risks, and Management Commentary
Management Commentary: The Company and co-developer Pfizer stated that the updated data demonstrate encouraging clinical activity in heavily pre-treated patients (median of four lines of prior therapy). The safety profile remains consistent with the known profile of palbociclib and previous vepdegestrant trials.
Risks and Contingencies: The filing notes that three of 46 patients discontinued palbociclib due to neutropenia. The data is from an investigational drug and does not guarantee future regulatory approval or commercial success.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for complete statistical tables and confidence intervals.
- Confirm the specific patient demographics and prior therapy history in the Phase 1b cohort (NCT04072952).
- Review the Company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor upcoming regulatory interactions regarding the Phase 3 dose recommendation (200 mg) based on these updated results.